Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L. A. Jokubaitis"'
Autor:
L A, Jokubaitis
Publikováno v:
British journal of clinical practice. Supplement.
Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::07c829c9c9faff06f7aa9afed12e0d9e
https://pubmed.ncbi.nlm.nih.gov/19496270
https://pubmed.ncbi.nlm.nih.gov/19496270
Autor:
L A, Jokubaitis
Publikováno v:
British journal of clinical practice. Supplement.
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. It is structurally distinct from the other currently availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1ea66861d2b8fa59d1d07a214a31b908
https://pubmed.ncbi.nlm.nih.gov/19489169
https://pubmed.ncbi.nlm.nih.gov/19489169
Publikováno v:
Journal of internal medicine. Supplement. 736
In this preliminary report of a 20-week trial, 66 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipidaemia who remained eligible after an 8-week dietary stabilization phase were randomly allocated to receive 20 mg of fluvasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a4ccec5cade305656a1c0b7140106ab
https://pubmed.ncbi.nlm.nih.gov/7986302
https://pubmed.ncbi.nlm.nih.gov/7986302
Publikováno v:
American journal of hypertension. 6(11 Pt 2)
Fluvastatin sodium (Lescol) is the first synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)-reductase inhibitor to be studied extensively in humans. Absorption of fluvastatin is complete and unaffected by the presence of food. Systemic exposur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a653d5fb9da7782bc7cc16507b13f4b
https://pubmed.ncbi.nlm.nih.gov/8297546
https://pubmed.ncbi.nlm.nih.gov/8297546
Publikováno v:
Drugs Affecting Lipid Metabolism ISBN: 9789401047463
Fluvastatin (FL), the first synthetic HMG-CoA reductase inhibitor, was administered to 946 hypercholesterolemic patients in four Phase III trials of 18 to 54 weeks duration. At 20 mg QPM, FL treatment resulted in a mean change in LDL-C of -20.5% (p 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::499fabb086eaf99593416904b57d0f03
https://doi.org/10.1007/978-94-011-1703-6_33
https://doi.org/10.1007/978-94-011-1703-6_33
